• No results found

Immune Cell Complexity in the Tumor

N/A
N/A
Protected

Academic year: 2021

Share "Immune Cell Complexity in the Tumor"

Copied!
2
0
0

Bezig met laden.... (Bekijk nu de volledige tekst)

Hele tekst

(1)

Cover Page

The handle http://hdl.handle.net/1887/79824 holds various files of this Leiden University dissertation.

Author: Salvagno, C.

Title: Immune cell complexity in the tumor microenvironment of breast cancer Issue Date: 2019-10-22

(2)

Immune Cell Complexity in the Tumor

Microenvironment of Breast Cancer

Camilla Salvagno

Camilla Salvagno Immune Cell Complexity in the TumorMicroenvironment of Breast Cancer

Immune Cell Complexity in the TumorMicroenvironment of Breast Cancer Camilla Salvagno

Referenties

GERELATEERDE DOCUMENTEN

2010, "Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer", Cancer letters, vol. &

Respondents who prefer Afrikaans films above English films are more influenced by all five of these factors; and film attendees who view three or more films in one month are more

Prognostic value of the immune status of tumors The immune status of tumors was classified as high in 18.9%, intermediate in 63.1% and low in 18.0% of the breast cancer cases..

Hayward SW, Thomson AA. Genome-wide analysis of AR binding and comparison with transcript expression in primary human fetal prostate fibroblasts and cancer associated

Robb, R.J., et al., Identification and expansion of highly suppressive CD8(+)FoxP3(+) regulatory T cells after experimental allogeneic bone marrow transplantation. Kiniwa, Y.,

concluded that PD-L1 expression on MC38 tumor cells was fully responsible for inhibiting antitumor T cell responses, with no additional role for PD-L1 on host cells, whereas the

In preparation for the culling programme, Pienaar, van Wyk and Fairall (1966) published ‘An aerial census of elephant and buffalo in the Kruger National Park and the

Title: Exploring and modulating the tumor immune microenvironment: Towards improving patient outcomes of immunotherapy in lung cancer. Issue